Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

One Centre, Single Ascending Dose and Double Blind Multiple Ascending Dose, Safety and Pharmacokinetics Phase I Study of CPL207280 Compound in Healthy Volunteers

Trial Profile

One Centre, Single Ascending Dose and Double Blind Multiple Ascending Dose, Safety and Pharmacokinetics Phase I Study of CPL207280 Compound in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CPL207-280CA (Primary) ; Metformin
  • Indications Diabetic neuropathies; Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Celon Pharma

Most Recent Events

  • 17 Aug 2021 Status changed from active, no longer recruiting to completed.
  • 29 Jun 2021 Results (n=24) of part A portion of this dose-escalation study with single oral administration of CPL207280 in healthy subjects in fasting conditions presented at the 81st Annual Scientific Sessions of the American Diabetes Association
  • 14 May 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top